March 16, 2026
Unleash the cure, leash the red tape
The bureaucracy blocking the chance at a cure
Red Tape vs Cures: Dog Dad, Tech Founder, and a Maze of No
TLDR: AI-tinkerers and a tech founder pushed experimental treatments, but the real fight was against endless red tape, not science. Comments split between “profit-first medicine,” safety vs. speed, and dark humor—while many ask why cheaper, faster trials abroad aren’t the norm in the U.S.
An AI-savvy dog dad in Sydney built a custom mRNA vaccine to fight his pup’s cancer—and the internet didn’t cheer the science so much as rage at the paperwork. He says the hardest part wasn’t the vaccine, it was the 100-page form and months of hoops just to treat his own dog. Cue echoes from the human side: GitLab co-founder Sid S. went “founder mode” on his cancer and beat the odds after plowing through a wall of rules; writer Jake Seliger, without deep pockets, couldn’t even get into key trials. The community saw a pattern: access for the rich, obstacles for everyone else.
Then the comments exploded. One camp screamed “profits over patients”, with tinfoilhatter claiming the system doesn’t want cures, it wants cash. Others snapped back with “Did you even read the article?”, accusing cynics of missing the point: safety is good, but this is bureaucratic overkill. Dark humor flew—“do my parents last, yours first” and a brutal “Didn’t Covid take care of that?”—sparking a slap-fight over ethics and empathy. Meanwhile, pragmatists asked: if Australia can run trials faster and cheaper with no extra safety issues, why can’t the U.S.? The mood: AI is making cures possible, but the red tape is making them theoretical.
Key Points
- •The article examines regulatory red tape that hinders experimental treatments in both veterinary and human contexts.
- •Paul Conyngham used AI to design a personalized mRNA vaccine for his dog and faced months of ethics paperwork to run a dog trial in Australia.
- •In the U.S., GitLab co-founder Sid Sijbrandij self-funded experimental therapies but encountered significant regulatory and institutional barriers; he has been relapse-free since 2025.
- •Writer Jake Seliger’s difficulty enrolling in trials without substantial resources underscores inequities created by complex procedures.
- •The author claims small early-stage trials can be run more cheaply and with less bureaucracy, noting Australia’s trials are 2.5–3× cheaper and faster than in the U.S.; they co-founded Clinical Trial Abundance in 2024 to improve in-human trial efficiency amid accelerating AI-driven progress.